DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Brain Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Brain Cancer Market is an evolving segment of the global healthcare landscape, driven by the increasing Brain Cancer prevalence of the disorder and the continuous development of innovative treatment options. The Brain Cancer market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Brain Cancer Market with DelveInsight’s In-Depth Report @ Brain Cancer Market Size
Key Takeaways from the Brain Cancer Market Report
- In November 2024:- Oblato Inc.- This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
- In November 2024:- MedSIR- This trial will study a type of advanced lung cancer that is defined as non-squamous non-small cell lung cancer (NSCLC) with active brain metastases (BMs). This type of cancer originates in peripheral lung tissue, which is composed of cancer cells that look different from normal lung cells when viewed under a microscope and is characterized by the presence of BMs, which indicates the spreading of such cancer cells into the brain.
- Among the 7MM, the US accounted for the highest incident cases of primary brain tumors in 2023, with around 23,000 cases; these numbers are expected to increase during the forecast period.
- According to the estimates, in the US, it is observed that brain tumor was most incident in the 40-64 years age group, followed by ≥65 years.
- Among the type-specific cases, the cases of Glioblastoma Multiforme accounted for the highest number of incident cases in 2023 in the US.
- Amongst EU4 and the UK, Italy accounted for the highest number of incident cases of the primary brain tumor, followed by Germany in 2023.
- The leading Brain Cancer Companies such as Orbus Therapeutics, Kazia Therapeutics, Bayer, MedImmune, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Servier, Genentech, Merck, Arbor Pharmaceuticals, Daiichi Sankyo, and others.
- Promising Brain Cancer Pipeline Therapies such as Nivolumab, Temozolomide, GLIADEL, hCRF, Afatinib, Dexanabinol, Dotarem®, HLX208, and others.
Stay ahead in the Brain Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Brain Cancer Market Outlook
Brain Cancer Epidemiology Segmentation in the 7MM
- Total incident cases of Primary Brain Tumors
- Brain Cancer Type-specific incident cases
- Brain Cancer Gender-specific incident cases
- Brain Cancer Grade-specific incident cases
- Brain Cancer Age-specific Distribution
Download the report to understand which factors are driving Brain Cancer epidemiology trends @ Brain Cancer Prevalence
Brain Cancer Marketed Drugs
- AVASTIN (bevacizumab): Genentech
AVASTIN is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor. It binds to the vascular endothelial growth factor with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors. AVASTIN is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. In December 2017, the US FDA granted full approval of AVASTIN for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. It was previously granted provisional approval in this setting under the US FDA’s accelerated approval program.
The active pharmaceutical ingredient in TEMODAR/TEMODAL is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly. It was granted US FDA approval in the treatment of recurrent anaplastic astrocytoma in 1999. Then, in March 2005, the US FDA approved TEMODAR for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Recently, in September 2023, the US FDA approved new and updated indications for TEMODAR capsules and injections, including for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma, and the treatment of adults with refractory anaplastic astrocytoma.
Brain Cancer Emerging Drugs
Vorasidenib is a small molecule and is a dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes in development for the treatment of IDH-mutant diffuse glioma. Vorasidenib works as a brain penetrant. It was granted Fast Track Designation in February 2023 and Breakthrough Therapy Designation in August 2023 by the US FDA. In the Phase III INDIGO trial (NCT04164901), vorasidenib demonstrated reduced tumor growth rate (TGR) and shrunk tumor volume, as measured by an independent radiology committee, while patients in the placebo arm saw continued growth in tumor volume.
- Paxalisib: Kazia Therapeutics
Paxalisib is a small molecule that inhibits PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. Paxalisib has been designed to cross the blood-brain barrier, and a wealth of experimental data shows that it does so very successfully. This feature of paxalisib is almost unique in this class of medicines and differentiates it from the approved products in the PI3K inhibitor class. The lead indication for paxalisib is glioblastoma. In July 2023, the US FDA granted Fast Track Designation to paxalisib in combination with radiation therapy for the treatment of patients with solid tumor brain metastases harboring PI3K pathway mutations. The drug is currently in an adaptive phase III study for potential registration called GBM AGILE.
Get In-Depth Knowledge on Brain Cancer Market Trends and Forecasts with DelveInsight @ Brain Cancer Treatment Market
Brain Cancer Treatment Market
The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy, and/or chemotherapy. Immunotherapy provides another opportunity for treatment in the market. It is a new promising and exciting area of treatment designed to trigger the body’s immune system to fight and halt tumor growth. Immunotherapy or “vaccine” therapy involves the induction of an immune response against an individual tumor. The treatments might include checkpoint inhibitors and cancer vaccines that utilize a tumor’s antigens. The ongoing research lights up the chance for immunotherapy in the coming years.
Scope of the Brain Cancer Market Report
- Coverage- 7MM
- Brain Cancer Companies- Orbus Therapeutics, Kazia Therapeutics, Bayer, MedImmune, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Servier, Genentech, Merck, Arbor Pharmaceuticals, Daiichi Sankyo, and others.
- Brain Cancer Pipeline Therapies- Nivolumab, Temozolomide, GLIADEL, hCRF, Afatinib, Dexanabinol, Dotarem®, HLX208, and others
- Brain Cancer Market Dynamics: Brain Cancer Market Drivers and Barriers
- Brain Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives
Unlock Strategic Insights with DelveInsight’s Comprehensive Brain Cancer Market Report @ Brain Cancer Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Brain Cancer Market Overview at a Glance
5 Key Events
6 Epidemiology and Market Forecast Methodology
7 Disease Background and Overview
8 Treatment
9 Treatment Algorithm
10 Epidemiology and Patient Population
11 Patient Journey
12 Marketed Drugs
13 Emerging Therapies
14 Brain Cancer: Seven Major Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
18 Reimbursement and Market Access
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Brain Cancer Market Size in the 7MM is expected to grow by 2034, estimated DelveInsight
